'Ozempic Face': What It Is, Why It Happens, and What You Can Do

What "Ozempic face" actually is

"Ozempic face" is a term popularised by dermatologists and aesthetics practitioners starting in 2022–23 to describe a pattern of facial changes seen in patients losing significant weight on GLP-1 drugs — specifically, a gaunt, hollow, or aged appearance resulting from facial volume loss.

The term is slightly misleading in two ways:

1. The drug does not cause the facial change directly. Ozempic, Wegovy, and other GLP-1 drugs do not have a specific mechanism that targets facial fat. The facial changes result from weight loss — losing fat overall, including fat in the face.

2. It is not unique to GLP-1 therapy. Significant rapid weight loss from any cause — bariatric surgery, dietary intervention, illness — produces similar facial changes. The phenomenon became prominent with GLP-1 drugs because the drugs produce faster and larger weight loss than most other interventions.

Why the face ages during weight loss

The face retains a youthful appearance through a combination of factors: skin elasticity, underlying fat padding (particularly in the buccal fat pad, temples, and under-eye areas), and bone and muscle support. These work together to create fullness and smooth skin contours.

When rapid weight loss occurs:

• Subcutaneous facial fat decreases. Fat depots in the temples, mid-cheek, buccal area, and under the eyes reduce in volume. This creates hollow temples, sunken cheeks, more prominent cheekbones, and deepened nasolabial folds.

• Skin may not retract fully. The dermis and epidermis need time to contract. Rapid weight loss allows less time than slow loss, meaning skin may appear loose or saggy before the contraction catches up.

• Neck and jawline changes. Jowling and neck laxity can appear or worsen as the fat that supported the jaw angle is lost.

The rate of loss matters. Patients who lose 15–25% of body weight over 12–18 months (typical for semaglutide or tirzepatide) are losing significant absolute fat volume. At a heavier starting weight, this can represent a large absolute volume of facial fat lost.

Who is most likely to notice Ozempic face

Age over 45. Skin elasticity decreases significantly with age. Younger patients with more collagen have better skin retraction; older patients are more likely to see loose skin that does not fully bounce back.

Higher percentage weight loss. Patients losing 20%+ of body weight are losing more facial fat in absolute terms.

Faster rate of loss. Rapid weight loss at the higher doses (tirzepatide 15 mg, semaglutide 2.4 mg) produces changes more quickly than the skin can adapt.

Starting with a thinner face. Patients who were not particularly round-faced before starting GLP-1 therapy have less facial fat reserve — volume loss is more visible on an already-angular face.

Is it permanent?

For most patients, the degree of visible facial change stabilises once weight loss stabilises. Some degree of skin retraction occurs as the body adjusts to the new weight over 6–12 months.

If GLP-1 therapy is discontinued and weight regains (which commonly occurs — see our article on weight regain after GLP-1 therapy), facial volume typically returns. This has led some patients to report that stopping the drug "fixed" Ozempic face — but this is at the cost of returning to the previous weight and its associated health consequences.

What can be done

Resistance training and protein

The most evidence-based strategy for mitigating Ozempic face is not cosmetic — it is the same protocol recommended for overall lean mass preservation:

• Resistance training preserves muscle in the face and neck as well as the body
• Adequate protein intake (1.2–1.6 g/kg) supports skin collagen and dermal integrity as well as muscle preservation
• A slower weight loss trajectory (achieved through dose management) gives the skin more time to adapt

Skincare

Skincare does not reverse volume loss but can improve skin quality and elasticity:

• Retinoids (retinol or prescription tretinoin) stimulate collagen production and improve skin texture. The most evidence-backed topical intervention for skin quality changes associated with weight loss.
• SPF 30+ sunscreen daily — UV exposure degrades collagen and accelerates the skin ageing process that is already being challenged by rapid weight loss.
• Hyaluronic acid serums improve surface hydration but do not address deeper volume loss.

Aesthetic procedures

Aesthetic practitioners have developed a growing practice area around GLP-1 facial changes. Common procedures:

Dermal fillers: Hyaluronic acid filler (Juvéderm, Restylane, Sculptra) can replace lost facial volume, particularly in the temples, mid-face, and nasolabial areas. Results last 12–24 months depending on product. Not permanent — requires repeat treatment.

Collagen-stimulating injectables: Poly-L-lactic acid (Sculptra) and calcium hydroxyapatite (Radiesse) stimulate the body's own collagen production over 3–6 months. Longer-lasting than HA fillers; better suited to diffuse volume loss than isolated hollowing.

Thread lifts: Minimal-invasive lifting procedures using dissolvable threads. Results are less predictable and less durable than surgical options.

Surgical: Facelifts (rhytidectomy) and fat transfer procedures are options for patients with significant skin laxity. Typically considered only when weight has stabilised.

The risk framing: is Ozempic face worth worrying about?

Context: GLP-1 therapy produces 15–25% weight loss, significantly reduces risk of cardiovascular events, type 2 diabetes, NAFLD, and sleep apnoea, and substantially improves quality of life for most patients.

The facial changes associated with significant weight loss are real. For some patients, they are cosmetically concerning. But they are a manageable aesthetic issue, not a health risk. The appropriate frame is: GLP-1 therapy has meaningful health benefits that substantially outweigh a cosmetic side effect that can be mitigated.

The aesthetics industry has benefited commercially from the "Ozempic face" framing. Some of the coverage has been disproportionate to the clinical significance of the phenomenon.

Summary

Ozempic face is weight-loss-related facial volume loss — not a drug-specific toxic effect. It is more prominent with rapid, large weight loss in older patients with less skin elasticity. Resistance training, protein adequacy, and a slower weight loss rate are the primary mitigation strategies. Dermal fillers and collagen-stimulating injectables are effective cosmetic treatments for patients who find the facial changes significant. The phenomenon should be contextualised against the substantial health benefits of GLP-1-assisted weight loss.